Cargando…

Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment

Detalles Bibliográficos
Autores principales:	Wallecha, Anu, Molli, Poonam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288711/ http://dx.doi.org/10.1186/2051-1426-2-S3-P63

Ejemplares similares

Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2013)

Lm-LLO-Based Immunotherapies and HPV-Associated Disease
por: Wallecha, Anu, et al.
Publicado: (2012)

A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial
por: Gnanandarajah, Josephine S, et al.
Publicado: (2014)

Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy
por: Molli, Poonam, et al.
Publicado: (2013)

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
por: Mkrtichyan, Mikayel, et al.
Publicado: (2013)

High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015)

Effect of listeriolysin O (LLO) secreted by listeria monocytogenes on apoptosis of macrophages derived from patients with macrophage activation syndrome- in vitro
por: Shiari, Reza, et al.
Publicado: (2014)

Targeted delivery of immunogenic antigen to the tumor microenvironment after irradiation facilitates tumor control
por: Wu, Tc, et al.
Publicado: (2013)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Cancer immunotherapy with multiple tumor antigen activated autologous T cells in patients with HBV related hepatocellular carcinoma
por: Han, Yanyan, et al.
Publicado: (2014)

Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
por: Jiang, Hong, et al.
Publicado: (2015)

A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
por: Lin, Po‐Lin, et al.
Publicado: (2017)

Single-step nanoparticle antigen presentation system for tumor immunotherapy
por: Kohlhapp, Frederick, et al.
Publicado: (2015)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Antibody targeted CpG for the immunotherapy of solid tumors
por: Epstein, Alan L, et al.
Publicado: (2015)

Dual-targeting nanoparticles for reprogrammed T cell responses in the tumor microenvironment
por: Kosmides, Alyssa K, et al.
Publicado: (2014)

Density of immunogenic antigens does not explain presence or absence of the T cell-inflamed tumor microenvironment in metastatic melanoma
por: Zha, Yuanyuan, et al.
Publicado: (2015)

Cancer testis antigen expression in triple negative breast cancer: Candidate targets for cancer immunotherapy?
por: Hendrickx, Wouter, et al.
Publicado: (2015)

LAG-3 and 4-1BB identify dysfunctional antigen-specific T cells in the tumor microenvironment and combinatorial LAG-3/4-1BB targeting gives synergistic tumor control
por: Williams, Jason B, et al.
Publicado: (2015)

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
por: Holmgaard, Rikke B, et al.
Publicado: (2013)

Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment
por: Broucek, Joseph, et al.
Publicado: (2014)

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
por: Berger, S Carolina, et al.
Publicado: (2014)

AnImPaLLO – onkologische Patientenleitlinien im Fokus
por: Meyer, Nora, et al.
Publicado: (2021)

A chimeric antigen receptor against prostate-specific membrane antigen, a tumor vasculature target
por: Santoro, Stephen P, et al.
Publicado: (2013)

Remodulation of the tumor microenvironment by regulatory T cells
por: Liu, Chang, et al.
Publicado: (2015)

Cytotoxic Activity of LLO Y406A Is Targeted to the Plasma Membrane of Cancer Urothelial Cells
por: Resnik, Nataša, et al.
Publicado: (2021)

Antigen-specific T cells conditioned with MDSC display a surprising increased anti-tumor activity after adoptive T cell-based immunotherapy
por: Raber, Patrick, et al.
Publicado: (2015)

IL-15 is an inflammatory mediator in the tumor microenvironment
por: Anthony, Scott M, et al.
Publicado: (2015)

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties
por: Williams, Jason, et al.
Publicado: (2013)

Egr2 targets identify a population of dysfunctional T cells in the tumor microenvironment with immune modulatory properties
por: Williams, Jason, et al.
Publicado: (2014)

Development of chimeric antigen receptor (CAR) T-cell immunotherapy for glioblastoma targeting epidermal growth factor receptor variant III (EGFRvIII)
por: Park, Anthony K, et al.
Publicado: (2015)

ARMADiLLO: a web server for analyzing antibody mutation probabilities
por: Martin Beem, Joshua S, et al.
Publicado: (2023)

Intra-patient intra-tumoral immune heterogeneity is evident at progression on targeted therapy and immunotherapy for melanoma
por: Reuben, Alexandre, et al.
Publicado: (2014)

Enrichment and expansion with nanoscale artificial antigen presenting cells for T cell adoptive immunotherapy
por: Perica, Karlo, et al.
Publicado: (2014)

Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants
por: Skarzynski, Martin, et al.
Publicado: (2015)

Antigen-specific TIL therapy for melanoma: a flexible platform for personalized cancer immunotherapy
por: Kelderman, Sander, et al.
Publicado: (2013)

Immunotherapy with patient-specific antigens selection reduced the metastasis of a cervical cancer patient
por: Han, Yanyan, et al.
Publicado: (2015)

Intratumoral injections of G100 (synthetic TLR4 agonist) increase trafficking of lentiviral vector-induced antigen-specific CD8 T cells to the tumor microenvironment
por: Albershardt, Tina C, et al.
Publicado: (2015)

The genetic landscape of the T cell non-inflamed tumor microenvironment in human solid tumors
por: Luke, Jason J, et al.
Publicado: (2015)

Immunotherapy targeting esophageal cancer stem cells
por: Yue, Dongli, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o152451isrlvpdfv5n66mjvb70